Bausch & Lomb
This article was originally published in The Gray Sheet
Executive Summary
Completes acquisition of hearing aid manufacturer Dahlberg with the approval of Dahlberg shareholders July 30. B&L acquired Dahlberg for about $139 mil. ($21 per share) under the terms of an agreement that had been modified to account for costs associated with addressing charges against Dahlberg by the Federal Trade Commission ("The Gray Sheet" May 24, I&W-9). Under the original letter of intent between the firms, B&L would have paid $158 million ($24 per share). B&L is consolidating the operations of its former hearing systems division into Golden Valley, Minnesota-based Dahlberg, which will operate as a subsidiary.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.